Actinogen Medical

Actinogen Medical EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Actinogen Medical (ACW.AX) as of Nov 13, 2026 is -95.11 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -60.99 % — a change of 55.94% (lower).

EBIT/Assets

-95.11 %

YoY

55.94%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Actinogen Medical is 2026 -95.11 % . Operating Income to Assets Ratio (EBIT/Assets) of Actinogen Medical was 2025 -60.99 % . It decreases by 55.94% lower compared to the previous year.

The Actinogen Medical EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
-59.22 AUD
Jan 1, 2020
-74.66 AUD
Jan 1, 2021
-32.12 AUD
Jan 1, 2022
-56.52 AUD
Jan 1, 2023
-104.37 AUD
Jan 1, 2024
-60.24 AUD
Jan 1, 2025
-60.99 AUD
Jan 1, 2026
-95.11 AUD
The Actinogen Medical EBIT/Assets history
YEAREBIT/AssetsYoY
-95.11 %+55.94%
-60.99 %+1.25%
-60.24 %-42.28%
-104.37 %+84.65%
-56.52 %+75.95%
-32.12 %-56.98%
-74.66 %+26.07%
-59.22 %+11.65%
-53.05 %+17.81%
-45.03 %-23.08%
-58.54 %+68.12%
-34.82 %+5.36%
-33.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Actinogen Medical Stock analysis

What does Actinogen Medical do? Actinogen Medical Ltd, based in Sydney, Australia, is a clinical-stage biotechnology company operating in the Health Care sector. It focuses on developing novel treatments for cognitive impairment linked to neurological, psychiatric, and metabolic diseases caused by elevated cortisol levels. The company's lead compound, Xanamem, targets the 11B-HSD1 enzyme in the brain to reduce cortisol, with ongoing Phase II studies for Alzheimer’s Disease, Major Depressive Disorder, and Fragile X Syndrome. The firm has conducted research involving approximately 300 volunteers and patients. Actinogen Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Actinogen Medical stock

Operating Income to Assets Ratio (EBIT/Assets) of Actinogen Medical is -95.11 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of Actinogen Medical changed from -60.99 % to -95.11 %, representing a 55.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Actinogen Medical since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Actinogen Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Actinogen Medical

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Actinogen Medical